1
|
Raveloson H, Ben Hassen J, Koraib R, Jhouri A, Schlatter J. Appropriate prescription of cytobacteriological urine examinations in older adults. Urologia 2024:3915603241244936. [PMID: 38557329 DOI: 10.1177/03915603241244936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Cytobacteriological urine examinations (CBEU) are frequently ordered for the older adults, sometimes without straightforward indication and with the risk of prescribing empirical antibiotics. The aim of this study was to evaluate the relevance of the CBEU prescription and empiric antibiotic therapy in our geriatric hospital. Among 129 patients (mean age 84 years, sex ratio 0.69), 229 CBEU were collected with 20.9% of inappropriate indication. Cultures were sterile in 43% (n = 99) of cases and positive in 57% (n = 130) cases. Gram-negative bacilli dominated the isolated bacteria (76.9%) followed by gram-positive cocci (17.6%). In 113 patients, probabilistic antibiotic therapy was prescribed of which 68 treatments were initiated before the CBEU. Ceftriaxone and amoxicillin plus clavulanic acid were the main therapeutic option used representing 70.8% of cases. Antibiotic therapy was re-evaluated after 3 days in 74.3% of patients. Efforts to reduce the number of useless ECBUs by training doctors to follow official guidelines are a priority.
Collapse
Affiliation(s)
| | - Jihène Ben Hassen
- Assistance Publique des Hôpitaux de Paris, Hôpital Paul Doumer, Labruyère, France
| | - Rihab Koraib
- Assistance Publique des Hôpitaux de Paris, Hôpital Paul Doumer, Labruyère, France
| | - Aziza Jhouri
- Assistance Publique des Hôpitaux de Paris, Hôpital Paul Doumer, Labruyère, France
| | - Joël Schlatter
- Assistance Publique des Hôpitaux de Paris, Hôpital Paul Doumer, Labruyère, France
| |
Collapse
|
2
|
Schlatter J. Special Issue "Recent Advances in Oral Drug Delivery Development". Pharmaceuticals (Basel) 2023; 16:1289. [PMID: 37765097 PMCID: PMC10538212 DOI: 10.3390/ph16091289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 08/31/2023] [Indexed: 09/29/2023] Open
Abstract
This Special Issue, entitled "Recent Advances in Oral Drug Delivery Development", aims to demonstrate new advances and future trends in the field of oral drug delivery [...].
Collapse
Affiliation(s)
- Joël Schlatter
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Paul Doumer, Service de Pharmacie, 60140 Labruyère, France
| |
Collapse
|
3
|
Baud F, Ladjouzi N, Ben Hassen J, El Omeiri N, Raveloson H, Brondin L, Ben Rahal C, Ould Ouali C, Zouloumis G, Schlatter J. Paracetamol prescriptions in older people hospitalized in a French geriatric hospital. Health Sci Rep 2023; 6:e1565. [PMID: 37732103 PMCID: PMC10507803 DOI: 10.1002/hsr2.1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 08/30/2023] [Accepted: 08/31/2023] [Indexed: 09/22/2023] Open
Affiliation(s)
- Frederic Baud
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Nadia Ladjouzi
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Jihène Ben Hassen
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Nesrine El Omeiri
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Hendriniainia Raveloson
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Lucile Brondin
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Camille Ben Rahal
- Médecine gériatrique aigue, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Cid Ould Ouali
- Service de soins et réadaptation, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Georges Zouloumis
- Service de long séjour, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| | - Joël Schlatter
- Pharmacie, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisLabruyèreFrance
| |
Collapse
|
4
|
Ladjouzi N, Ben Hassen J, Mebarki I, Al Zoabi M, Alaysh A, Schlatter J. Successfully drug treatment for necrotizing fasciitis caused by Streptococcus pyogenes in 88-year-old patient. Clin Case Rep 2023; 11:e07633. [PMID: 37426685 PMCID: PMC10323722 DOI: 10.1002/ccr3.7633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 07/11/2023] Open
Abstract
Necrotizing fasciitis (NF) is a rare soft-tissue infection generally treated by emergency surgical intervention. We report a case of successfully drug treatment for NF in older patient with comorbidities thus avoiding surgical intervention.
Collapse
Affiliation(s)
- Nadia Ladjouzi
- Médecine gériatrique aigueHôpital Paul Doumer, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Jihène Ben Hassen
- Médecine gériatrique aigueHôpital Paul Doumer, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Idir Mebarki
- Médecine gériatrique aigueHôpital Paul Doumer, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Mohamad Al Zoabi
- Médecine gériatrique aigueHôpital Paul Doumer, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Adel Alaysh
- Médecine gériatrique aigueHôpital Paul Doumer, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Joël Schlatter
- Pharmacie, Hôpital Paul DoumerAssistance Publique des Hôpitaux de ParisParisFrance
| |
Collapse
|
5
|
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur AS, Negbane A, Hadchouel A, Schlatter J, Cotteret C. Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease. Pharmaceutics 2023; 15:pharmaceutics15030957. [PMID: 36986818 PMCID: PMC10056843 DOI: 10.3390/pharmaceutics15030957] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 02/22/2023] [Accepted: 03/03/2023] [Indexed: 03/18/2023] Open
Abstract
L-Methionine (Met) is an essential alpha-amino acid playing a key role in several metabolic pathways. Rare inherited metabolic diseases such as mutations affecting the MARS1 gene encoding methionine tRNA synthetase (MetRS) can cause severe lung and liver disease before the age of two years. Oral Met therapy has been shown to restore MetRS activity and improve clinical health in children. As a sulfur-containing compound, Met has a strongly unpleasant odor and taste. The objective of this study was to develop an optimized pediatric pharmaceutical formulation of Met powder, to be reconstituted with water, to obtain a stable oral suspension. Organoleptic characteristics and physicochemical stability of the powdered Met formulation and suspension were evaluated at three storage temperatures. Met quantification was assessed by a stability-indicating chromatographic method as well as microbial stability. The use of a specific fruit flavor (e.g., strawberry) with sweeteners (e.g., sucralose) was considered acceptable. No drug loss, pH changes, microbiological growth, or visual changes were observed at 23 ± 2 °C and 4 ± 2 °C with the powder formulation for 92 days, and the reconstituted suspension for at least 45 days. The developed formulation facilitates the preparation, administration, the dose adjustment and palatability of Met treatment in children.
Collapse
Affiliation(s)
- Benjamin Querin
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
| | - Arnaud Schweitzer-Chaput
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
| | - Salvatore Cisternino
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
- Université Paris Cité, Inserm UMRS 1144, Faculté de Pharmacie, 4, Avenue de l’Observatoire, F-75006 Paris, France
- Correspondence: ; Tel.: +33-1-44-495-191
| | - Sylvain Auvity
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
- Université Paris Cité, Inserm UMRS 1144, Faculté de Pharmacie, 4, Avenue de l’Observatoire, F-75006 Paris, France
| | - Anne-Sophie Fauqueur
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
| | - Abdel Negbane
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
| | - Alice Hadchouel
- Service de Pneumologie Pédiatrique, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris, AP-HP, 149 rue de Sèvres, F-75015 Paris, France
- Institut Necker Enfants Malades (INEM), INSERM U1151, Faculté de Médecine, Université Paris Cité, 156 rue de Vaugirard, F-75015 Paris, France
| | - Joël Schlatter
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
- Service Pharmacie, Hôpital Paul Doumer, Assistance Publique des Hôpitaux de Paris, AP-HP, 1 rue de l’hôpital, F-60140 Labruyère, France
| | - Camille Cotteret
- Service Pharmacie, Hôpital Universitaire Necker—Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, F-75015 Paris, France
| |
Collapse
|
6
|
Romdhani A, Lehmann S, Schlatter J. Discontinuation of Antidepressants in Older Adults: A Literature Review. Ther Clin Risk Manag 2023; 19:291-299. [PMID: 37013196 PMCID: PMC10066696 DOI: 10.2147/tcrm.s395449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Accepted: 01/30/2023] [Indexed: 03/30/2023] Open
Abstract
Polypharmacy increases the risk of unbearable side effects, drug-drug interactions, and hospitalizations in geriatric patients. The iatrogenic risk of inadequate management of antidepressants is very important in this population. Therefore, primary care physicians and geriatricians have the responsibility of the optimization of antidepressants prescriptions. Our work is a literature review of the European and the international guidelines regarding the management of antidepressants. We reviewed the PubMed database and Google scholar for articles and reviews from 2015. We also screened relevant articles for more references and searched the web for available European guidelines relevant to our topic. We divided our findings into four main inquiries that are Indication, effectiveness, tolerability, and iatrogenic risks. Poor or absence of effectiveness should lead to a readjustment of the treatment plan. In case of unbearable side effects, antidepressants should be stopped, and alternative non-pharmacological therapies should be proposed. Doctors should look out for drug-drug interaction risks in this population and constantly adjust the prescription. Prescription of antidepressants is not always evidence based which leads to heavy iatrogenic consequences. We suggest a simple 4-questions-algorithm that aims to remind doctors of the basics of good practice and helps in the process of deprescribing an antidepressant in older adults.
Collapse
Affiliation(s)
- Ahmed Romdhani
- Département Medico-Universitaire de Gériatrie, Hôpital Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), Labruyère, France
- Correspondence: Ahmed Romdhani, Email
| | - Stephanie Lehmann
- Pôle d’hospitalisation et relation ville-hôpital, Centre Hospitalier de Saint Marcellin, Isére, France
| | - Joël Schlatter
- Pharmacie, Hôpital Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), Labruyère, France
| |
Collapse
|
7
|
Ladjouzi N, Romdhani A, Zouloumis G, Ould Ouali C, Jhouri A, Schlatter J. Reassessment of Treatments in a Long-Term Care Unit. Gerontol Geriatr Med 2023; 9:23337214231156030. [PMID: 36819230 PMCID: PMC9932759 DOI: 10.1177/23337214231156030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 01/11/2023] [Accepted: 01/21/2023] [Indexed: 02/16/2023] Open
Abstract
The risks of iatrogenic medication related adverse events are high among older patients. Assessing prescriptions is critical to prevent overusing, underusing, or misusing medications. The aim of this study is to evaluate the prescription reassessment in older patients hospitalized in long-term care unit. Among the 30 patients (M age = 83 years, woman 66%), polymedication was present, patients taking 5 to 18 drugs (mean 11 drugs). The length of stay varied from 92 days to 4.5 years (mean 564 ± 430 days). The prescription reassessment of the patients hospitalized in our long-term care unit varied from 1 to 125 days with a mean of 16 days. Plan the prescription reassessment could reduce the iatrogenic medication in weakened patients.
Collapse
Affiliation(s)
- Nadia Ladjouzi
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France
| | - Ahmed Romdhani
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France
| | - Georges Zouloumis
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France
| | - Cid Ould Ouali
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France
| | - Aziza Jhouri
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France
| | - Joël Schlatter
- Hôpital Paul Doumer, Assistance
Publique des Hôpitaux de Paris, Labruyère, France,Joël Schlatter, Hôpital Paul Doumer,
Assistance Publique des Hôpitaux de Paris, 1 route de l’hôpital, Labruyère
60140, France.
| |
Collapse
|
8
|
Astuto MC, Benford D, Bodin L, Cattaneo I, Halldorsson T, Schlatter J, Sharpe RM, Tarazona J, Younes M. Applying the adverse outcome pathway concept for assessing non-monotonic dose responses: biphasic effect of bis(2-ethylhexyl) phthalate (DEHP) on testosterone levels. Arch Toxicol 2023; 97:313-327. [PMID: 36336711 DOI: 10.1007/s00204-022-03409-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 10/24/2022] [Indexed: 11/09/2022]
Abstract
Male reproduction is one of the primary health endpoints identified in rodent studies for some phthalates, such as DEHP (Bis(2-ethylhexyl) phthalate), DBP (Dibutyl phthalate), and BBP (Benzyl butyl phthalate). The reduction in testosterone level was used as an intermediate key event for grouping some phthalates and to establish a reference point for risk assessment. Phthalates, and specifically DEHP, are one of the chemicals for which the greatest number of non-monotonic dose responses (NMDRs) are observed. These NMDRs cover different endpoints and situations, often including testosterone levels. The presence of NMDR has been the subject of some debate within the area of chemical risk assessment, which is traditionally anchored around driving health-based guidance values for apical endpoints that typically follow a clear monotonic dose-response. The consequence of NMDR for chemical risk assessment has recently received considerable attention amongst regulatory agencies, which confirmed its relevance particularly for receptor-mediated effects. The present review explores the relationship between DEHP exposure and testosterone levels, investigating the biological plausibility of the observed NMDRs. The Adverse Outcome Pathway (AOP) concept is applied to integrate NMDRs into Key Event Relationships (KERs) for exploring a mechanistic understanding of initial key events and possibly associated reproductive and non-reproductive adverse outcomes.
Collapse
Affiliation(s)
- M C Astuto
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy.
| | - D Benford
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - L Bodin
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - I Cattaneo
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - T Halldorsson
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy.,Faculty of Food Science and Nutrition, University of Iceland, Reykjavik, Iceland
| | - J Schlatter
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - R M Sharpe
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - J Tarazona
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| | - M Younes
- European Food Safety Authority, Methodology and Scientific Support Unit and Working Group on Non-Monotonic Dose Responses, Parma, Italy
| |
Collapse
|
9
|
Ladjouzi N, Romdhani A, Zouloumis G, Schlatter J. Inappropriate proton pump inhibitor lansoprazole prescription in older adults hospitalized in long-term care unit. Ir J Med Sci 2022:10.1007/s11845-022-03207-3. [PMID: 36333472 PMCID: PMC10390349 DOI: 10.1007/s11845-022-03207-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 10/26/2022] [Indexed: 11/06/2022]
Abstract
Abstract
Purpose
We evaluated the use of the PPI treatment by physicians in older adults hospitalized in a long-term care unit.
Methods
We included 40 patients aged 65 years or older with a lansoprazole prescription hospitalized in long-term care unit from January 2018 to January 2022. Patient characteristics, gastroduodenal history, dose of lansoprazole, indication, days of prescription, and number of medications were collected from electronic patient records.
Results
The mean age of patients was 84.2 ± 9.3. Patients were taking between 5 and 24 (mean = 12.7, SD = 4.4) medications overall with 15 patients taking low dose of aspirin (75 mg daily) and 8 patients taking an antiplatelet. Most patients (82.5%) received once-daily lansoprazole treatment, 55% of whom took a dose of 15 mg. Five patients were treated with the maximum dose of lansoprazole 30 mg twice daily. Only seven patients had an appropriate indication. The minimum of treatment time was 3 days and the maximum was 1198 days; moreover, 24 patients (60%) were still in treatment.
Conclusion
Few PPI prescriptions had an indication in the patient’s electronic record. Prescriptions were ongoing with no date of discontinuation or re-evaluation.
Collapse
|
10
|
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags. Eur J Hosp Pharm 2022; 29:353-358. [PMID: 33658227 PMCID: PMC9614118 DOI: 10.1136/ejhpharm-2020-002620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 01/30/2021] [Accepted: 02/09/2021] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES To determine the physicochemical stability of pemetrexed diarginine in original vials, and after dilution in two commonly used infusion fluids (0.9% sodium chloride, 5% dextrose) in polyolefin bags, stored under refrigeration (2-8°C) or at ambient temperature (22-25°C) exposed to light. METHODS Stability of pemetrexed diarginine injection concentrate was determined in the original glass vials with closed-system transfer device. Diluted pemetrexed diarginine infusion solutions were aseptically prepared by dilution of pemetrexed diarginine concentrate with either 0.9% sodium chloride or dextrose 5% in polyolefin bags, in amounts yielding pemetrexed diarginine concentrations of 4, 9 and 12 mg/mL. Test solutions were stored under refrigeration (2-8°C) or at ambient temperature (22-25°C) exposed to light. Pemetrexed diarginine concentrations were determined throughout a 14-day storage period using a stability-indicating HPLC assay. In addition, test solutions were visually examined for colour change and precipitation. RESULTS Pemetrexed diarginine injection concentrate with closed-system transfer device is shown to be physicochemically stable for up to 4 days when stored under refrigeration and for 1 day at room temperature. A browning of the pemetrexed diarginine concentrate solutions appeared 0n day 2 when stored at ambient temperature and on day 5 under refrigeration. Pemetrexed diarginine diluted in dextrose 5% and 0.9% sodium chloride was physicochemically stable for up to 4 days when stored under refrigeration and for 1 day at room temperature. A browning of the diluted solutions appeared on day 2 when stored at room temperature and on day 5 when stored under refrigeration. CONCLUSIONS Pemetrexed diarginine concentrate for solution stored under refrigeration with closed-system transfer device can be retained as a residual to reduce product losses. The analytical stability of pemetrexed diarginine in dextrose 5% and 0.9% sodium chloride under refrigeration enables our centralised unit to prepare this drug in advance.
Collapse
Affiliation(s)
- Fabrice Vidal
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| | - Camille Cotteret
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| | - Abdel Negbane
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| | - Maria Sebti
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| | - Mélanie Hinterlang
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| | | | - Joël Schlatter
- Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France
| |
Collapse
|
11
|
Cotteret C, Secretan PH, Gilles-Afchain L, Rousseau J, Vidal F, Salguero-Hernandez G, Batista J, Valverde V, Guitton J, Cisternino S, Schlatter J. External contamination of antineoplastic drug vials: an occupational risk to consider. Eur J Hosp Pharm 2022; 29:284-286. [PMID: 32978219 PMCID: PMC9660623 DOI: 10.1136/ejhpharm-2020-002440] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 09/03/2020] [Accepted: 09/15/2020] [Indexed: 11/03/2022] Open
Abstract
Risk management for workers involved in the handling and preparation of cytotoxic drugs is challenging. This study aims to investigate drug contamination of the exterior surfaces of cytotoxic drug vials. Two batches of commercially available cytotoxic drugs in unprotected vials (ifosfamide, etoposide phosphate and cyclophosphamide) and plastic shrink wrap vials (doxorubicin, cytarabine and busulfan) were tested without removing the flip-off cap or the plastic wrap, and without prewashing. The results showed significant trace amounts of cytotoxic drugs on the exterior surfaces in both unprotected (eg, cyclophosphamide, ifosfamide) and protected plastic shrink wrap vials (eg, cytarabine), indicating that the secondary packaging of protected vials does not systematically prevent exposure to the handlers. These results focus on the need for guidelines to prevent cytotoxic vial contamination and safety recommendations for staff in the handling and storage of these vials.
Collapse
Affiliation(s)
- Camille Cotteret
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| | | | | | - Julia Rousseau
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| | - Fabrice Vidal
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| | | | - Jonathan Batista
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| | - Vicky Valverde
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| | - Jerome Guitton
- Pharmacy, Centre Régional de Lutte Contre le Cancer Centre Léon Bérard, Lyon, France
| | - Salvatore Cisternino
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
- Faculté de Pharmacie, Université Paris Descartes, Inserm UMR-S1144, Paris, France
| | - Joël Schlatter
- Pharmacie clinique, Hôpital universitaire Necker-Enfants Malades, Paris, France
| |
Collapse
|
12
|
Nguyen-Khoa T, Hatton A, Drummond D, Aoust L, Schlatter J, Martin C, Ramel S, Kiefer S, Gachelin E, Stremler N, Cosson L, Gabsi A, Remus N, Benhamida M, Hadchouel A, Fajac I, Munck A, Girodon E, Sermet-Gaudelus I. Reclassifying inconclusive diagnosis for Cystic Fibrosis with new generation sweat test. Eur Respir J 2022; 60:13993003.00209-2022. [PMID: 35777769 DOI: 10.1183/13993003.00209-2022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 04/19/2022] [Indexed: 11/05/2022]
Affiliation(s)
- Thao Nguyen-Khoa
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France.,Laboratoires de Biochimie & du Centre Régional de Dépistage Néonatal- Ile-de-France, Hôpital Necker-Enfants Malades, Paris, France.,Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France
| | - Aurélie Hatton
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France
| | - David Drummond
- Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.,Service de Pneumo-Allergologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Laura Aoust
- Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.,Service de Pneumo-Allergologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Joël Schlatter
- Pharmacie Clinique, Hôpital Necker-Enfants Malades, Paris, France
| | - Clémence Martin
- Centre de Ressource et de Compétence de la Mucoviscidose (CRCM), Explorations-Fonctionnelles, Hôpital Cochin, Paris, France
| | - Sophie Ramel
- CRCM, Hôpital Hélio Marin, Fondation Ildys, Roscoff, France
| | - Sébastien Kiefer
- CRCM Pédiatrique, Hôpital de Mercy, Centre Hospitalier Régional Universitaire, Nancy, France
| | - Elsa Gachelin
- Service de Pédiatrie, Hôpital Félix-Guyon, Centre Hospitalier Universitaire, Saint Denis, France
| | | | | | - Asma Gabsi
- CRCM, Hôpital André Mignot, Le Chesnay, France
| | - Natascha Remus
- CRCM, Hôpital Inter-Communal de Créteil, Créteil, France
| | - Myriam Benhamida
- CRCM, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Alice Hadchouel
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France.,Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.,Service de Pneumo-Allergologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Isabelle Fajac
- Université de Paris, Paris, France.,Centre de Ressource et de Compétence de la Mucoviscidose (CRCM), Explorations-Fonctionnelles, Hôpital Cochin, Paris, France
| | - Anne Munck
- Laboratoires de Biochimie & du Centre Régional de Dépistage Néonatal- Ile-de-France, Hôpital Necker-Enfants Malades, Paris, France
| | - Emmanuelle Girodon
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France.,Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, Paris, France
| | - Isabelle Sermet-Gaudelus
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France .,Université de Paris, Paris, France.,Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.,Service de Pneumo-Allergologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| |
Collapse
|
13
|
Rousseau J, Zribi K, Cotteret C, Marcais A, Winter S, Salguero‐Hernandez G, Cisternino S, Schlatter J. Subcontracting sterile pediatric and adult chemotherapy preparations activity: A global risk analysis. Health Sci Rep 2022; 5:e571. [PMID: 35769357 PMCID: PMC9209798 DOI: 10.1002/hsr2.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 03/08/2022] [Accepted: 03/10/2022] [Indexed: 11/06/2022] Open
Affiliation(s)
- Julia Rousseau
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
| | - Kaouther Zribi
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
| | - Camille Cotteret
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
| | - Ambroise Marcais
- Service d'Hématologie Adulte Assistance‐Publique des Hôpitaux de Paris Paris France
| | - Sarah Winter
- Service d'Immunologie, Hématologie et Rhumatologie pédiatrique, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
- Imagine institute INSERM U1163 Paris France
| | - Gabriel Salguero‐Hernandez
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
| | - Salvatore Cisternino
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
- Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM UMR_S1144 Université de Paris Paris France
| | - Joël Schlatter
- Pharmacie, Hôpital Universitaire Necker—Enfants Malades Assistance‐Publique des Hôpitaux de Paris Paris France
- Pharmacie, Hôpital Paul Doumer Assistance‐Publique des Hôpitaux de Paris, AP‐HP Labruyère France
| |
Collapse
|
14
|
Ould Ouali C, Ladjouzi N, Tamas K, Raveloson H, Ben Hassen J, El Omeiri N, Zouloumis G, Al Zoabi MM, Asadi M, Jhouri A, Schlatter J. Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review. Geriatrics (Basel) 2022; 7:geriatrics7010022. [PMID: 35200527 PMCID: PMC8872498 DOI: 10.3390/geriatrics7010022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 02/14/2022] [Accepted: 02/18/2022] [Indexed: 12/15/2022] Open
Abstract
The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tocilizumab treatment could be a potential therapeutic option for old patients. We report the case of an 88-year-old man with COVID-19 disease who presented at the admission with anemia, fever, oxygen desaturation (92%), and inflammatory syndrome (C-reactive protein (CRP) at 182.5 mg/L; reference range <5.0 mg/L). After remaining CRP level increase (206.6 mg/L), Tocilizumab administration led to rapid clinical outcome and resolution of his inflammatory syndrome. This case report represents a supplementary data confirming the efficacy and safety of Tocilizumab for COVID-19 in elderly patients.
Collapse
Affiliation(s)
- Cid Ould Ouali
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Nadia Ladjouzi
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Khidher Tamas
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Hendriniaina Raveloson
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Jihene Ben Hassen
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Nesrine El Omeiri
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Georges Zouloumis
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Mohamed Moataz Al Zoabi
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Muneer Asadi
- Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France; (C.O.O.); (N.L.); (K.T.); (H.R.); (J.B.H.); (N.E.O.); (G.Z.); (M.M.A.Z.); (M.A.)
| | - Aziza Jhouri
- Pharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France;
| | - Joël Schlatter
- Pharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France;
- Correspondence:
| |
Collapse
|
15
|
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S, Schlatter J. Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions. Am J Health Syst Pharm 2021; 78:825-831. [PMID: 33611378 DOI: 10.1093/ajhp/zxab066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
PURPOSE Ketamine is an anesthetic agent commonly used for the induction of anesthesia. Ketamine is also given to control pain, for treatment of posttraumatic stress disorder, and to induce bronchodilation in refractory asthma. Moreover, ketamine therapy is gaining ground as an intervention for patients with treatment-resistant depression and individuals who have depression with serious suicidal ideation. Recently, the drug has been used to disrupt maladaptive reward memories in individuals with harmful alcohol consumption behaviors. The stability of 10-mg/mL and 50-mg/mL ketamine solutions stored at ambient and refrigeration temperatures was assessed over 90 days. METHODS Three batches of 10-mg/mL and 50-mg/mL ketamine solutions were stored for 90 days under two temperature conditions (2°C-8°C and 22°C-25°C) in amber plastic bottles. Chemical stability was assessed using a stability-indicating high-performance liquid chromatography assay. At each study time, visual inspection and pH assessments of ketamine concentration and pH were conducted. RESULTS For all solutions tested at each condition, the ketamine concentration remaining was at least 98% of the initial concentration over 90 days of storage. Throughout the study period, solution pH remained stable and the color and odor of the suspensions remained unchanged. CONCLUSION Extemporaneously compounded 10-mg/mL and 50-mg/mL oral solutions of ketamine prepared in a flavored suspending excipient and stored in amber polypropylene plastic bottles were stable for at least 90 days at both ambient and refrigeration temperatures.
Collapse
Affiliation(s)
- Dimitri Ancedy
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France
| | - Maria Sebti
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France
| | - Martine Postaire
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France
| | - Fabrice Vidal
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France
| | - Salvatore Cisternino
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France.,Université de Paris, Faculté de Santé, Paris, France
| | - Joël Schlatter
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP.CUP, Paris, France
| |
Collapse
|
16
|
Hinterlang M, Gendron A, Fleury T, Rieutord A, Vrana A, Schlatter J, Annereau M. Design and stability of pediatric oral formulation of imatinib. J Oncol Pharm Pract 2021; 28:337-342. [PMID: 33522386 DOI: 10.1177/1078155221991200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Imatinib is a protein-tyrosine kinase inhibitor which is currently only commercially available as a tablet dosage form in the strength of 100mg and 400mg. The elaboration of new oral liquid formulations is suitable in pediatrics and for patients who have difficulties to swallow, notably in the absence of commercial forms. This enables the adaptation of dosage and secure the administration. OBJECTIVES The formulation of an oral pediatric solution of imatinib at a concentration of 30 mg/mL and the evaluation of its stability for the treatment of pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia. METHODS The physicochemical stability parameters: appearance, pH, osmolality, and drug content of formulation were evaluated for 30 days when stored at 2-8°C. Concentration of solution was measured with a validated method using high performance liquid chromatography (HPLC) coupled with an absorbance UV detector. Equally, microbiological stability was performed. RESULTS The remaining imatinib concentration was at least 95% of the initial concentration after 30 days stored in fridge temperature. No changes were observed regarding the physical properties of the formulation during the study period. CONCLUSIONS The stability study showed that the imatinib oral solution at a concentration of 30 mg/mL provides an alternative option at the commercial tablet dosage forms for pediatric patients and patients who have difficulties to swallow.
Collapse
Affiliation(s)
- Mélanie Hinterlang
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | | | - Thomas Fleury
- Pharmacie, Institut Gustave Roussy, Villejuif, France
| | | | | | - Joël Schlatter
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Maxime Annereau
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé, Paris, France
| |
Collapse
|
17
|
El Mershati S, Thouvenin A, Secretan PH, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. Formulation and stability study of hydroxychloroquine sulfate oral suspensions. Pharm Dev Technol 2021; 26:328-334. [PMID: 33428504 DOI: 10.1080/10837450.2021.1871918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Hydroxychloroquine is an antimalarial drug indicated in the treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and more recently proposed in COVID-19 therapy. Hydroxychloroquine is only available in tablets which are not easy to administer for pediatric and geriatric patients, and patients unable to swallow such as patients found in intensive care units. The aim of this work was to develop and optimize a ready to use liquid hydroxychloroquine formulation and to carry out the corresponding chemical and microbiological stability studies. The formulation was evaluated for ease of preparation, physical properties, and palatability. Its stability was performed at ambient temperature and under refrigeration. After 6 months of stability testing, the results showed no pH change, no drug loss, no microbial development, and no visual change. The formulation, employing excipients in a range that EMA has recommended, showed chemical and microbiological stability for at least 6 months even in the worst storage conditions.
Collapse
Affiliation(s)
- Sarah El Mershati
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Agathe Thouvenin
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Philippe-Henri Secretan
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Pascale De Lonlay
- Reference Center for Inherited Metabolic Diseases, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.,INSERM, Paris, France
| | - Caroline Tuchmann-Durand
- Imagine Institut des Maladies Génétiques, Paris, France and Department of Biotherapy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Salvatore Cisternino
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.,Faculté de Pharmacie, Université de Paris, Paris, France
| | - Joël Schlatter
- Department of Pharmacy, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| |
Collapse
|
18
|
Haddad N, Gueneau R, Alanio A, Bretagne S, Jouannard B, Delliere S, Caux F, Schlatter J, Brun S, Lortholary O, Laroche L. Dermatophytose corporelle étendue à Trichophyton mentagrophytes résistant à la terbinafine, liée à une mutation du gène de la squalène époxydase. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Bouchand C, Nguyen D, Secretan PH, Vidal F, Guery R, Auvity S, Cohen JF, Lanternier F, Lortholary O, Cisternino S, Schlatter J. Voriconazole topical cream formulation: evidence for stability and antifungal activity. Int J Antimicrob Agents 2020; 56:106083. [PMID: 32659465 DOI: 10.1016/j.ijantimicag.2020.106083] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 06/22/2020] [Accepted: 07/05/2020] [Indexed: 01/01/2023]
Abstract
Systemic use of voriconazole (VCZ) might be restricted by adverse events, such as hepatotoxicity and neurotoxicity, or drug-drug interactions. Topical VCZ application to skin may help to treat local infection more effectively and limit unwanted whole-body exposure. Topical VCZ cream was stable for 90 days when refrigerated. A patient with cutaneous Fusarium solani infection on his right forearm was successfully treated with topical 1% VCZ cream after failure of oral VCZ treatment.
Collapse
Affiliation(s)
- Camille Bouchand
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France
| | - David Nguyen
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France
| | | | - Fabrice Vidal
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France
| | - Romain Guery
- Paris Descartes University, Infectious Diseases and Tropical Medicine Department, Necker-Enfants Malades Hospital, AP-HP, IHU Imagine, Paris, France
| | - Sylvain Auvity
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France; Inserm UMR-S 1144, Université Paris Descartes, Paris, France
| | - Jeremie F Cohen
- Paris Descartes University, Infectious Diseases and Tropical Medicine Department, Necker-Enfants Malades Hospital, AP-HP, IHU Imagine, Paris, France
| | - Fanny Lanternier
- Paris Descartes University, Infectious Diseases and Tropical Medicine Department, Necker-Enfants Malades Hospital, AP-HP, IHU Imagine, Paris, France; Institut Pasteur, National Reference Center for Invasive Mycoses and Antifungals, Molecular Mycology Unit, CNRS UMR2000, Paris, France
| | - Olivier Lortholary
- Paris Descartes University, Infectious Diseases and Tropical Medicine Department, Necker-Enfants Malades Hospital, AP-HP, IHU Imagine, Paris, France; Institut Pasteur, National Reference Center for Invasive Mycoses and Antifungals, Molecular Mycology Unit, CNRS UMR2000, Paris, France
| | - Salvatore Cisternino
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France; Inserm UMR-S 1144, Université Paris Descartes, Paris, France
| | - Joël Schlatter
- Department of Pharmacy, Necker - Enfants Malades Hospital, AP-HP, Paris, France.
| |
Collapse
|
20
|
Cotteret C, Pham YV, Marcais A, Driessen M, Cisternino S, Schlatter J. Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report. BMC Pregnancy Childbirth 2020; 20:231. [PMID: 32306909 PMCID: PMC7168968 DOI: 10.1186/s12884-020-02928-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2019] [Accepted: 04/07/2020] [Indexed: 12/20/2022] Open
Abstract
Background Hodgkin lymphoma (HL) is the most common hematological malignancy during pregnancy. The first-line treatment for HL in pregnancy is the standard ABVD regimen without any drug and/or dose adjustment. However, data on chemotherapy during twin pregnancies are sparse, and a better understanding of the mechanisms involved in exposure to and the toxic effects of anticancer drugs in the fetuses is needed. Case presentation A 41-year-old dichorionic diamniotic pregnant patient was given ABVD treatment for HL at a gestational age of 28 weeks and 3 days. The patient received 2 cycles of chemotherapy with a 15-day therapeutic window including an actual 25 mg/m2 dose of doxorubicin per cycle. Unlike the female twin, the male twin presented four days after birth a left cardiac dysfunction. Doxorubicin cardiotoxicity in the male newborn was also supported by high blood levels of troponin. At one month of age, echocardiography findings were normal. We investigated literature data on physiological aspects of pregnancy that may influence doxorubicin pharmacokinetics, and pharmacodynamic and pharmacokinetic data on the use of doxorubicin in pregnancy. We detailed the role of the transporters in doxorubicin placenta distribution, and tried to understand why only one fetus was affected. Conclusions Fetal safety depends at least on maternal doxorubicin pharmacokinetics.Because of drug interactions (i.e. drug metabolism and drug transport), care should always be taken to avoid maternal pharmacokinetic variability. The toxic effects were discrepant between the dizygotic twins, suggesting additional fetus-specific pharmacokinetic/pharmacodynamic factors in doxorubicin toxicity.
Collapse
Affiliation(s)
- Camille Cotteret
- Hôpital universitaire Necker - Enfants malades, Pharmacie, F-75015, Paris, France
| | - Yen-Vi Pham
- Hôpital universitaire Necker - Enfants malades, Pharmacie, F-75015, Paris, France
| | - Ambroise Marcais
- Hôpital universitaire Necker - Enfants malades, Hématologie adultes, F-75015, Paris, France
| | - Marine Driessen
- Hôpital universitaire Necker - Enfants malades, gynécologie-obstétrique, F-75015, Paris, France
| | - Salvatore Cisternino
- Hôpital universitaire Necker - Enfants malades, Pharmacie, F-75015, Paris, France.,Inserm UMR-S 1144, Team "Blood-brain barrier in brain pathophysiology and therapy", Université Paris Descartes, F-75006, Paris, France
| | - Joël Schlatter
- Hôpital universitaire Necker - Enfants malades, Pharmacie, F-75015, Paris, France.
| |
Collapse
|
21
|
Videau M, Cotteret C, Sibon D, Schlatter J. [Retrospective cohort study of rituximab biosimilar (Rixathon®) adverse events in adult hematology and pediatric nephrology]. Rev Med Liege 2020; 75:185-189. [PMID: 32157845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The purpose of this study was to describe rituximab biosimilar safety in adult hematology and pediatric nephrology units. Adverse events were classified using the Common Terminology Criteria for Adverse Events (CTCAE) classification. Fifty adult patients were enrolled for a total of 126 cures and 11 pediatric patients for a total of 24 biosimilar cures. Among adults, three infusion-related reactions of biosimilar occurred : a bronchospasm, a reaction at the injection site and emesis. Among children, infusion-related reactions were: a bronchospasm, an injection site reaction, an emesis, and diarrhea. For adults, the most common adverse events included neutropenia (13.5 %) with 9 severe grade 3/4 cases, anemia (8.7 %), grade 1 thrombocytopenia (6.3 %), asthenia (2.4 %), infection (2.4 %), and chills (1.6 %). For children, a case of severe grade 4 neutropenia, a fever and conjunctivitis were observed. Results of this study show a confident safety profile of rituximab biosimilar in adults and children in «real life».
Collapse
Affiliation(s)
- M Videau
- Service de Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - C Cotteret
- Service de Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - D Sibon
- Service d'Hématologie adulte, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - J Schlatter
- Service de Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| |
Collapse
|
22
|
Belo S, Touchard J, Secretan PH, Vidal F, Boudy V, Cisternino S, Schlatter J. Stability of Pentobarbital Hydrogel for Rectal Administration in Pediatric Procedural Sedation. Hosp Pharm 2020; 56:332-337. [PMID: 34381270 DOI: 10.1177/0018578719901276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose: Pentobarbital is a sedative agent to limit children motion during computed tomography or magnetic resonance imaging (MRI) and ensures the successful completion of the imaging procedure. However, data on rectal drug formulation and its stability in practice are not available. The aim of this study was to formulate and evaluate the stability of a ready-to-use rectal pentobarbital gel. Methods: The formulation consisted of a hydrated gel containing 25 mg/mL of pentobarbital sodium, packaged in 10-mL amber glass bottles and stored at either 22°C to 25°C or 2°C to 8°C. At each predetermined time point, samples were taken for visual inspection, pH measurement, and analysis by a validated stability-indicating high-performance liquid chromatography (HPLC) method. The viscosity parameters of the hydrogel formulation were assessed. Results: The freshly prepared rectal formulations appeared clear, colorless, and particular-free with pH readings of 9.75 to 9.83. Over the 90 days of the study period, there was no significant change in appearance or pH values for all stability samples. The HPLC results confirmed the chemical stability when stored at 2°C to 8°C or at 22°C to 25°C. Conclusion: Pentobarbital hydrogel 25 mg/mL are stable chemically at least 90 days and can be administered to children for an effective and fast sedation.
Collapse
Affiliation(s)
- Sephora Belo
- Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | | | | | - Fabrice Vidal
- Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | - Vincent Boudy
- Agence Générale des Equipements et Produits de Santé, Paris, France
- PSL Research University, Paris, France
- CNRS, UTCBS UMR 8258, Paris, France
- Université Paris Descartes, France
- INSERM, UTCBS U 1022, Paris, France
| | - Salvatore Cisternino
- Hôpital Universitaire Necker-Enfants Malades, Paris, France
- Université Paris Descartes, France
| | - Joël Schlatter
- Hôpital Universitaire Necker-Enfants Malades, Paris, France
| |
Collapse
|
23
|
Dubray Q, Diallo T, Loeuillet R, Andre E, Fauqueur AS, Poil S, Thromas N, Secretan PH, Cisternino S, Schlatter J. Occupational risks evaluation in a centralized antineoplastic agent preparation unit. SAGE Open Med 2019; 7:2050312119866970. [PMID: 31384466 PMCID: PMC6661790 DOI: 10.1177/2050312119866970] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 07/10/2019] [Indexed: 11/15/2022] Open
Abstract
Objective: The global professional risk assessment applied to the central unit of
antineoplastic agent preparations is part of a mandatory approach required
by the European legislation for workers. This study identified the hazardous
situations related to the staff activity and then enabled the preparation of
a formal plan of occupational prevention. Methods: The nature of study approved by a working group constituted by experts was
the global risk analysis. After identifying the hazardous situations, the
global risk analysis estimated the risk level of each hazardous situation
based on a criticality score, including severity and frequency. The global
risk analysis highlighted the initial and residual risks after establishing
a plan to reduce the high criticality risks. Results: Hence, 33 unacceptable hazardous situations were identified. The critical
categories of professional risks were “Product, emissions, and waste risks”
with 17 (55%) hazardous situations; “Psychosocial risk factors” with 8 (24%)
hazardous situations; and “Risks related to work equipment” with 6 (18%)
hazardous situations. Once the risk reduction plan was in place, all
hazardous situations were considered under control. The corrective actions
led to a reorganization of human resources, the update of protection
protocols, and optimization of ergonomic work tools. Staff-specific medical
monitoring and regular surface contamination tests have been scheduled
annually. In addition, initial and continuous training, specific to product
and waste risks, has been updated. Conclusion: The global professional risk assessment related to centralized antineoplastic
agent preparation unit generated failure in our system and enabled
corrective actions for staff safety.
Collapse
Affiliation(s)
- Quentin Dubray
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Taibou Diallo
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Richard Loeuillet
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Emilie Andre
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | | | - Sandrine Poil
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Nathalie Thromas
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | | | - Salvatore Cisternino
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France.,Faculté de pharmacie de Paris, Université Paris Descartes, Paris, France.,INSERM UMR-S 1144, Paris, France
| | - Joël Schlatter
- Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| |
Collapse
|
24
|
Schlatter J, Cisternino S. Stability of warfarin sodium flavoured preservative-free oral liquid formulations. Eur J Hosp Pharm 2019; 25:e98-e101. [PMID: 31157077 DOI: 10.1136/ejhpharm-2017-001281] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 05/22/2017] [Accepted: 06/05/2017] [Indexed: 11/03/2022] Open
Abstract
Objectives This study was designed to assess the physicochemical stability of warfarin sodium liquid formulations stored at room temperature and under refrigeration. Methods Formulations of warfarin sodium 1mg/mL were prepared from either powder or tablets dispersed in mixture containing deionised water, glycerin, sodium phosphate and strawberry alcohol-free concentrate flavour and stored in amber glass bottles at 25°C and 4°C. Stability indicating high-performance liquid chromatography assay procedure was used to analyse the concentration of the drug at the time of preparation and on days 7, 14, 21, 30, 45, 60 and 90. Changes in colour, taste and pH, as well as visual evidence of precipitation, were assessed for physicochemical instability. Results Between day 0 and day 90, the pH of the powder and tablet formulations stored at 25°C decreased by -1.40 units and -1.16 units, respectively. There were minor changes in pH for both formulations stored at 4°C. The formulation from powder stored at 25°C and 4°C maintained at least 90% of the initial warfarin concentration for 30 days and 45 days, respectively. The formulation from tablets stored at 25°C and 4°C maintained at least 90% of initial warfarin concentration for 21 days and 30 days, respectively. Conclusion Warfarin sodium in flavoured preservative-free formulation from powder is recommended and stable in amber glass bottles for at least 30 days stored at 25°C and 45 days stored at 4°C.
Collapse
Affiliation(s)
- Joël Schlatter
- Pharmacie Clinique, Hôpital Universitaire Necker - Enfants Malades, Paris, France
| | - Salvatore Cisternino
- Pharmacie Clinique, Hôpital Universitaire Necker - Enfants Malades, Paris, France.,Faculté de Pharmacie, UMR-S 1144, Université Paris Descartes, Paris, France
| |
Collapse
|
25
|
Saint-Marc P, Ratiney R, Schlatter J. Challenges in Implementing an E-Learning Education Program for Syringe Pump Use. Int J Nurs Educ Scholarsh 2019; 16:ijnes-2017-0079. [PMID: 30673627 DOI: 10.1515/ijnes-2017-0079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Accepted: 09/04/2018] [Indexed: 11/15/2022]
Abstract
To prevent the incidence of risks imputable to human error during the process of preparing the infusion pump, clarity in teaching and learning are required. Because traditional classroom training is difficult and time-consuming, the aim of the present study was to challenge the implementation of an e-learning education program for syringe pump use. The impact of the e-learning program was evaluated with 100 nurses between March and June 2016. The e-learning program significantly increased general baseline knowledge in syringe pump use; however, aspects of the program confused participants. The feedback from 98 % of nurses on the e-learning program was that it was effective in helping them with this skill. However, only 54 % opted for the e-learning program versus traditional training. The present study showed nurses preferred a blended learning format. Based on our hospital incident and error reports, this study shows local training requires a specific approach strategy for syringe pump education.
Collapse
Affiliation(s)
| | | | - Joël Schlatter
- Hopital universitaire Necker-Enfants Malades, Pharmacie, 75743Paris, France
| |
Collapse
|
26
|
Cotteret C, Marry S, Loeuillet R, Videau M, Cisternino S, Schlatter J. A virtual centralized cytotoxic preparation unit simulation to evaluate the pharmacy staff knowledge. J Oncol Pharm Pract 2019; 25:1187-1194. [PMID: 30626271 DOI: 10.1177/1078155218821426] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND The risk of medication errors related to drug preparation unit cannot be totally avoided because of human interference. The aim of this study is to investigate the background and knowledge of the pharmacy staff by replicating the cytotoxic preparation unit with potential errors. METHODS A 10-m2 room was provided to duplicate the centralized chemotherapy unit with three areas reproducing virtually the equipment preparation bench, the isolator, and the dispensing bench. The 14 situations selected by experts were integrated to each corresponded area. For each participant, a form was given and answers were analyzed by two independent experts. Statistical processing data were performed using GraphPad Prism® software. RESULTS A total of 19 professionals participated in error simulation workshop over a one-month period. The overall rate of correct responses was 58 ± 19%. In five situations, correct responses rate was lower than 50%: wrong drug batch related to the preparation sheet (40%), inappropriate sterilizing conditions (15%), the time on the preparation sheet provides an expired expiry date for melphalan preparation (45%), a maximum drug dose exceeded (25%), the dispensing form not corresponds to the preparation sheet and final product label (30%). The rate of correct responses was 45 ± 25% for professionals not specifically dedicated to chemotherapy preparation. The overall satisfaction workshop rate was 8.7 ± 1.0 out of 10. CONCLUSION This study showed the importance of training programs to sensitize personal staff to the risks of chemotherapy preparation and prevent errors.
Collapse
Affiliation(s)
- Camille Cotteret
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| | - Stéphanie Marry
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| | - Richard Loeuillet
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| | - Margaux Videau
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| | - Salvatore Cisternino
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France.,2 Inserm UMR-S 1144, Team "Blood-brain barrier in brain pathophysiology and therapy", Université Paris Descartes, Paris, France
| | - Joël Schlatter
- 1 Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| |
Collapse
|
27
|
Schlatter J, Kabiche S, Sellier N, Fontan JE. Oral pentobarbital suspension for children sedation during MR imaging. Annales Pharmaceutiques Françaises 2018; 76:286-290. [DOI: 10.1016/j.pharma.2018.03.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 03/02/2018] [Accepted: 03/03/2018] [Indexed: 10/17/2022]
|
28
|
Geraudie B, Kabiche S, Rigal M, Malki M, Fontan JE, Jacolot A, Schlatter J. Preliminary hazard analysis applied to outsourcing sterile chemotherapy preparations. J Oncol Pharm Pract 2018; 25:1078155218785239. [PMID: 29933726 DOI: 10.1177/1078155218785239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
Background Our hospital organization raised the possibilities of outsourcing their sterile pediatric chemotherapy preparations to another hospital conditional on analyzing the potential hazardous events that need to be anticipated. Methods The study was conducted by a multidisciplinary working group from September 2015 to January 2016 with the support of a risk manager. A list of hazardous situations that could occur during outsourcing process was assessed. First, a map of hazardous situations was developed by crossing outsourcing processes divided into phases classified as critical or not. Second, a map of risk was established by crossing potential consequences of these hazardous situations and elaborating corrective actions to reduce the initial risks. Results The map of hazardous situations identified 183 relevant hazardous situations, 78 of which were considered high priority and 154 scenarios were developed. Slightly more than half of these hazardous situations concerned information system (30%), human resources (14%), and management (11%). The generic hazards of information system and human generated 37 (24%) and 41 (27%) scenarios, respectively. To reduce critical risks, 33 corrective actions were proposed. Working time required was estimated at 35 days. The subcontractor personnel for this new organization included an estimated extra time of 0.7-pharmacist working day and 1.4-pharmacy dispenser working day. Conclusions The preliminary hazard analysis method appeared to apply to our system of outsourcing sterile cytotoxic preparations in another hospital. Regardless, this analysis is complex and requires time and expertise.
Collapse
Affiliation(s)
- Bastien Geraudie
- 1 Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bobigny, France
| | - Sofiane Kabiche
- 2 Hôpital Jean Verdier, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bondy, France
| | - Marthe Rigal
- 1 Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bobigny, France
| | - Myriam Malki
- 1 Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bobigny, France
| | - Jean-Eudes Fontan
- 2 Hôpital Jean Verdier, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bondy, France
| | - Anne Jacolot
- 1 Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine-Saint-Denis (HUPSSD), Bobigny, France
| | - Joël Schlatter
- 3 Hôpital Universitaire Necker - Enfants Malades, Paris, France
| |
Collapse
|
29
|
Schlatter J, Nguyen D, Zamy M, Kabiche S, Fontan JE, Cisternino S. Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use. Eur Spine J 2017; 28:21-30. [DOI: 10.1007/s00586-017-5387-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Revised: 07/24/2017] [Accepted: 11/05/2017] [Indexed: 11/24/2022]
|
30
|
Hfaiedh N, Kabiche S, Delescluse C, Balde IB, Merlin S, Carret S, de Pontual L, Fontan JE, Schlatter J. Performing a preliminary hazard analysis applied to administration of injectable drugs to infants. J Eval Clin Pract 2017; 23:875-881. [PMID: 28471070 DOI: 10.1111/jep.12748] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 02/28/2017] [Accepted: 03/01/2017] [Indexed: 12/27/2022]
Abstract
RATIONALE, AIMS AND OBJECTIVES Errors in hospitals during the preparation and administration of intravenous drugs to infants and children have been reported to a rate of 13% to 84%. This study aimed to investigate the potential for hazardous events that may lead to an accident for preparation and administration of drug injection in a pediatric department and to describe a reduction plan of risks. METHODS The preliminary hazard analysis (PHA) method was implemented by a multidisciplinary working group over a period of 5 months (April-August 2014) in infants aged from 28 days to 2 years. The group identified required hazard controls and follow-up actions to reduce the error risk. To analyze the results, the STATCART APR software was used. RESULTS During the analysis, 34 hazardous situations were identified, among 17 were quoted very critical and drawn 69 risk scenarios. After follow-up actions, the scenarios with unacceptable risk declined from 17.4% to 0%, and these with acceptable under control from 46.4% to 43.5%. CONCLUSION The PHA can be used as an aid in the prioritization of corrective actions and the implementation of control measures to reduce risk. The PHA is a complement of the a posteriori risk management already exists.
Collapse
Affiliation(s)
- Nadia Hfaiedh
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Sofiane Kabiche
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Catherine Delescluse
- Service Pédiatrie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Issa-Bella Balde
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Sophie Merlin
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Sandra Carret
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Loïc de Pontual
- Service Pédiatrie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Jean-Eudes Fontan
- Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Joël Schlatter
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades - APHP, Paris, France
| |
Collapse
|
31
|
Abstract
OBJECTIVE Bariatric surgery offers a highly effective mode of treatment for obese patients. Some procedures such as bypass cause an alteration in normal gastrointestinal tract with possible consequences for the uptake of orally administered drugs. METHODS We assessed the literature to ascertain whether the use of oral drugs and especially oral contraceptives is effective and adequate after bariatric surgery. RESULTS The bioavailability of drugs could be affected by the solubility and pH of the modified medium after bariatric surgery and by the loss of gastrointestinal transporters. Bariatric surgery could potentially result in a transient change in the absorption of drugs such as analgesics, antibiotics, antiarrhythmics, anticoagulants, psychotropic, and oral contraceptive drugs. Effective contraception is especially critical in the postoperative period, and implants might be representing a safe contraceptive method in women undergoing bariatric surgery. CONCLUSION Each drug will have to be evaluated with respect to its site of absorption and its mechanism of absorption, with special attention on parameters influencing the effectiveness of the absorption processes.
Collapse
Affiliation(s)
- Joël Schlatter
- *Dr. Joël Schlatter, Service Pharmacie, Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France,
| |
Collapse
|
32
|
Beck W, Kabiche S, Balde IB, Carret S, Fontan JE, Cisternino S, Schlatter J. Stability of suxamethonium in pharmaceutical solution for injection by validated stability-indicating chromatographic method. J Clin Anesth 2016; 35:551-559. [PMID: 27871592 DOI: 10.1016/j.jclinane.2016.09.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 08/24/2016] [Accepted: 09/06/2016] [Indexed: 11/18/2022]
Abstract
STUDY OBJECTIVE To assess the stability of pharmaceutical suxamethonium (succinylcholine) solution for injection by validated stability-indicating chromatographic method in vials stored at room temperature. METHODS The chromatographic assay was achieved by using a detector wavelength set at 218 nm, a C18 column, and an isocratic mobile phase (100% of water) at a flow rate of 0.6 mL/min for 5 minutes. The method was validated according to the International Conference on Harmonization guidelines with respect to the stability-indicating capacity of the method including linearity, limits of detection and quantitation, precision, accuracy, system suitability, robustness, and forced degradations. RESULTS Linearity was achieved in the concentration range of 5 to 40 mg/mL with a correlation coefficient higher than 0.999. The limits of detection and quantification were 0.8 and 0.9 mg/mL, respectively. The percentage relative standard deviation for intraday (1.3-1.7) and interday (0.1-2.0) precision was found to be less than 2.1%. Accuracy was assessed by the recovery test of suxamethonium from solution for injection (99.5%-101.2%). CONCLUSION Storage of suxamethonium solution for injection vials at ambient temperature (22°C-26°C) for 17 days demonstrated that at least 95% of original suxamethonium concentration remained stable.
Collapse
Affiliation(s)
- William Beck
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Sofiane Kabiche
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Issa-Bella Balde
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Sandra Carret
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Jean-Eudes Fontan
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Salvatore Cisternino
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France
| | - Joël Schlatter
- Service Pharmacie, Hôpital Jean Verdier-AP-HP, Hôpitaux universitaires de Paris-Seine-Saint-Denis, Avenue du 14 juillet, 93140 Bondy, France.
| |
Collapse
|
33
|
Haidar A, Kabiche S, Majoul E, Balde IB, Fontan JE, Cisternino S, Schlatter J. Stability-Indicating High-Performance Liquid Chromatography Assay for the Determination of Sulthiame in Pharmaceutical Dosage Forms. Anal Chem Insights 2016; 11:59-64. [PMID: 27625574 PMCID: PMC5013865 DOI: 10.4137/aci.s38656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 04/25/2016] [Accepted: 05/06/2016] [Indexed: 11/05/2022]
Abstract
A stability-indicating assay by reversed-phase high performance liquid chromatography method was developed and validated for the determination of sulthiame (STM). The chromatographic separation was achieved on a reversed-phase NovaPack C18 column and an isocratic mobile phase consisting of deionized water:methanol (70:30, v/v). The flow rate was 1.0 mL/min (ultraviolet detection at 210 nm). The STM was separated within 2.83 min. The linearity of the method was demonstrated in the range of 20.0–200.0 μg/mL and a coefficient of determination of r2 = 0.9999. The limits of detection and quantification were 4.2 and 9.5 μg/mL, respectively. The intraday and interday precisions were less than 1%. Accuracy of the method ranged from 98.3% to 101.7%, with a relative standard deviation of <1%. STM was degraded by accelerated breakdown in alkaline, acidic, or oxidative stress conditions. This method allows accurate and reliable determination of STM for drug stability assay in pharmaceutical studies.
Collapse
Affiliation(s)
- Ammar Haidar
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Sofiane Kabiche
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Elyes Majoul
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Issa-Bella Balde
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Jean-Eudes Fontan
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Salvatore Cisternino
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| | - Joël Schlatter
- Service de Pharmacie, Hôpital Jean Verdier, APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis, Bondy, France
| |
Collapse
|
34
|
Abstract
Adapted forms for administration to infants are limited. The proposed study was performed to propose oral liquid formulations of idebenone in Ora-Plus and either Ora-Sweet or Ora-Sweet SF, Ora-Blend, Ora-Blend SF and Inorpha. Each formulation was stored in 30 ml amber glass bottle at 5 or 25 °C for 90 days. Idebenone contents in these suspensions, determined by a stability-indicating high-performance liquid chromatography method, remained stable at least 90 days in Inorpha when stored at the two temperatures. In Ora-Blend, the stability was estimated at 14 days and in other suspensions at 20 days at the two temperatures. After 90 days storage, the pH of Ora-Plus and Ora-Sweet or Ora-Sweet SF changed between -0.10 and -0.25 units. For others suspensions, the pH changes were not significant (< -0.09 unit). No change was observed in color, odor or visual microbiology. To conclude, we recommended the use of idebenone in Inorpha vehicle stable for at least 90 days at 25 °C.
Collapse
Affiliation(s)
- Joël Schlatter
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Elodie Bourguignon
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Elyes Majoul
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Sofiane Kabiche
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Issa-Bella Balde
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Salvatore Cisternino
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| | - Jean-Eudes Fontan
- a Service Pharmacie , Hôpital Jean Verdier - APHP, Hôpitaux Universitaires de Paris-Seine-Saint-Denis , Bondy , France
| |
Collapse
|
35
|
Leduc-Souville B, Schlatter J. Gestion des excréta des personnes âgées traités par chimiothérapie anticancéreuse. Presse Med 2016; 45:532-7. [DOI: 10.1016/j.lpm.2015.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Accepted: 04/10/2015] [Indexed: 11/28/2022] Open
|
36
|
Schlatter J, Kabiche S, Balde IB, Majoul E, Cisternino S, Fontan JE. Stability of Pentobarbital in Water and Oral Pediatric Suspensions. Ann Pharmacother 2016; 50:245-6. [PMID: 26728367 DOI: 10.1177/1060028015625655] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
37
|
Kombath S, Balde IB, Carret S, Kabiche S, Cisternino S, Fontan JE, Schlatter J. Stability-Indicating HPLC Assay for Determination of Idebenone in Pharmaceutical Forms. J Anal Methods Chem 2015; 2015:835986. [PMID: 26605105 PMCID: PMC4641926 DOI: 10.1155/2015/835986] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Accepted: 10/07/2015] [Indexed: 06/05/2023]
Abstract
A stability-indicating method was validated for the determination in pharmaceutical forms of idebenone a coenzyme Q10-like compound. The assay was achieved by liquid chromatography analysis using a reversed-phase C18 column and a detector set at 480 nm. The optimized mobile phase consisted of isocratic flow rate at 1.0 mL/min for 3 min with methanol. The linearity of the assay was demonstrated in the range of 3.0 to 8.0 mg/mL with a correlation coefficient r (2) > 0.998. The limits of detection and quantification were 0.03 and 0.05 mg/mL, respectively. The intraday and interday precisions were less than 1.0%. Accuracy of the method ranged from 98.6 to 101.5% with RSD < 0.6%. Specificity of the assay showed no interference from tablets components and breakdown products formed by alkaline, acidic, oxidative, sunlight, and high temperature conditions. This method allows accurate and reliable determination of idebenone for drug stability assay in pharmaceutical studies.
Collapse
Affiliation(s)
- Sonoube Kombath
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Issa-Bella Balde
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Sandra Carret
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Sofiane Kabiche
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Salvatore Cisternino
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Jean-Eudes Fontan
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| | - Joël Schlatter
- Service Pharmacie, Hôpital Jean-Verdier, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires de Paris-Seine-Saint-Denis, avenue du 14 Juillet, 93140 Bondy, France
| |
Collapse
|
38
|
Chiadmi F, Schlatter J. Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma. Anal Chem Insights 2015; 10:17-22. [PMID: 26339186 PMCID: PMC4551303 DOI: 10.4137/aci.s25554] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Revised: 06/03/2015] [Accepted: 06/19/2015] [Indexed: 11/26/2022]
Abstract
This study aimed to develop a solid-phase extraction gas chromatography-selected ion monitoring-mass spectrometry method for the determination of methadone (MDN) and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in human plasma. The linear response was obtained over the concentration range from 10 to 2000 ng/mL for MDN and EDDP. The absolute recoveries of MDN and EDDP were 95.9%–98.9% and 94.8%–102.4%, with relative standard deviation (RSD) ranging from 1.8% to 2.7% and 1.8% to 3.9%, respectively. The intra- and interday precisions were found to be less than 5% for both analytes. The limits of detection of MDN and EDDP were 4 and 5 ng/mL, respectively. The presented method was convenient for therapeutic drug monitoring and pharmacokinetic studies in patients on heroin-assisted MDN therapy.
Collapse
Affiliation(s)
- Fouad Chiadmi
- Department of Forensic Laboratory, Jean Verdier Hospital-APHP, University Hospitals of Paris Seine Saint-Denis, Bondy, France
| | - Joël Schlatter
- Department of Forensic Laboratory, Jean Verdier Hospital-APHP, University Hospitals of Paris Seine Saint-Denis, Bondy, France. ; Department of Pharmacy, Jean Verdier Hospital-APHP, University Hospitals of Paris Seine Saint-Denis, Bondy, France
| |
Collapse
|
39
|
Abstract
OBJECTIVES The physical and chemical stability of a preservative-free oral solution of hydrocortisone succinate was studied at different pH values and storage temperatures. METHODS Oral solutions of hydrocortisone 1 mg/mL were prepared by dissolving hydrocortisone succinate powder in citrate buffers at pH 4.0, 5.5, and 6.5, or with sterile water (pH 7.4) stored in amber glass vials. Three identical samples of the formulations were prepared and stored under refrigeration (3-7°C), ambient temperature (20-22°C) and high temperature (29-31°C). A 200-μL sample was withdrawn from each of the 3 samples immediately after preparation and at 1, 7, 14, 21, and 35 days. Samples were assayed in duplicate using stability-indicating liquid chromatography. Stability was determined by evaluating the percentage of the initial concentration remaining at each time point; stability was defined as the retention of at least 90% of the initial concentration of hydrocortisone succinate. RESULTS At least 92% of the initial hydrocortisone succinate concentration in solutions pH 5.5, 6.5, and 7.4 remained throughout the 14-day study period under refrigeration. There were no detectable changes in color, odor, or pH and no visible microbial growth in these samples. In other storage conditions, hydrocortisone succinate was rapidly degraded. CONCLUSIONS The hydrocortisone succinate preservative-free oral solutions at pH 5.5, 6.5, or 7.4 are chemically stable when stored under refrigeration for at least 14 days. They provide flexible and convenient dosage forms without any preservatives for pediatric patients.
Collapse
Affiliation(s)
- Julie Chappe
- Department of Pharmacy, The University Hospital of Jean Verdier-APHP, Bondy, France
| | - Névine Osman
- Department of Pharmacy, The University Hospital of Jean Verdier-APHP, Bondy, France
| | - Salvatore Cisternino
- Department of Pharmacy, The University Hospital of Jean Verdier-APHP, Bondy, France
| | - Jean-Eudes Fontan
- Department of Pharmacy, The University Hospital of Jean Verdier-APHP, Bondy, France
| | - Joël Schlatter
- Department of Pharmacy, The University Hospital of Jean Verdier-APHP, Bondy, France
| |
Collapse
|
40
|
Hardy A, Dorne JLCM, Aiassa E, Alexander J, Bottex B, Chaudhry Q, Germini A, Nørrung B, Schlatter J, Verloo D, Robinson T. Editorial: Increasing robustness, transparency and openness of scientific assessments. EFSA J 2015. [DOI: 10.2903/j.efsa.2015.e13031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
41
|
Chapy H, Smirnova M, André P, Schlatter J, Chiadmi F, Couraud PO, Scherrmann JM, Declèves X, Cisternino S. Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol 2014; 18:pyu001. [PMID: 25539501 PMCID: PMC4368859 DOI: 10.1093/ijnp/pyu001] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The rate of entry of cocaine into the brain is a critical factor that influences neuronal plasticity and the development of cocaine addiction. Until now, passive diffusion has been considered the unique mechanism known by which cocaine crosses the blood-brain barrier. METHODS We reassessed mechanisms of transport of cocaine at the blood-brain barrier using a human cerebral capillary endothelial cell line (hCMEC/D3) and in situ mouse carotid perfusion. RESULTS Both in vivo and in vitro cocaine transport studies demonstrated the coexistence of a carrier-mediated process with passive diffusion. At pharmacological exposure level, passive diffusion of cocaine accounted for only 22.5% of the total cocaine influx in mice and 5.9% in hCMEC/D3 cells, whereas the carrier-mediated influx rate was 3.4 times greater than its passive diffusion rate in vivo. The functional identification of this carrier-mediated transport demonstrated the involvement of a proton antiporter that shared the properties of the previously characterized clonidine and nicotine transporter. The functionnal characterization suggests that the solute carrier (SLC) transporters Oct (Slc22a1-3), Mate (Slc47a1) and Octn (Slc22a4-5) are not involved in the cocaine transport in vivo and in vitro. Diphenhydramine, heroin, tramadol, cocaethylene, and norcocaine all strongly inhibited cocaine transport, unlike benzoylecgonine. Trans-stimulation studies indicated that diphenhydramine, nicotine, 3,4-methylenedioxyamphetamine (ecstasy) and the cathinone compound 3,4-methylenedioxypyrovalerone (MDPV) were also substrates of the cocaine transporter. CONCLUSIONS Cocaine transport at the BBB involves a proton-antiporter flux that is quantitatively much more important than its passive diffusion. The molecular identification and characterization of this transporter will provide new tools to understand its role in addictive mechanisms.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Salvatore Cisternino
- Variabilité de réponse aux psychotropes, INSERM, U1144, 75006 Paris, France (Drs. Chapy, Smirnova, André, Scherrmann, Declèves, Cisternino); Université Paris Descartes, UMR-S 1144, Paris, F-75006, France (Drs. Chapy, Smirnova, André, Scherrmann, Declèves, Cisternino); Université Paris Diderot, UMR-S 1144, Paris, F-75013, France (Drs. Chapy, Smirnova, André, Scherrmann, Declèves, Cisternino); Assistance publique hôpitaux de Paris, AP-HP, Jean Verdier, Bondy, F-93140, France (Drs. Schlatter, Chiadmi, Cisternino); INSERM, U1016, Institut Cochin, 75014, Paris, France (Dr. Couraud); CNRS, UMR8104, Paris, France (Dr. Couraud); Université Paris Descartes, Sorbonne Paris Cité, Paris, France (Dr. Couraud).
| |
Collapse
|
42
|
Chiadmi F, Schlatter J. Buprenorphine and norbuprenorphine determination in mice plasma and brain by gas chromatography-mass spectrometry. Anal Chem Insights 2014; 9:9-16. [PMID: 24653644 PMCID: PMC3956859 DOI: 10.4137/aci.s13515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 12/18/2013] [Accepted: 12/20/2013] [Indexed: 11/18/2022]
Abstract
A gas chromatography tandem mass spectrometry method for quantification of buprenorphine (BUP) and norbuprenorphine (NBUP) in brain and plasma samples from mice was developed and validated. Analytes were extracted from the brain or plasma by solid phase extraction and quantified within 20 minutes. Calibration was achieved by linear regression with a 1/x weighting factor and d4-buprenorphine internal standard. All products were linear from 1 to 2000 ng/mL with a correlation of determination >0.99. Assay accuracy and precision of back-calculated standards were within ±10%. The lower limit of quantification for both BUP and NBUP from the brain and plasma was 1 ng/mL. This sensitive and specific method can be used for the investigation of BUP mechanism of action and clinical profile.
Collapse
Affiliation(s)
- Fouad Chiadmi
- Laboratoire de toxicologie de médecine légale, Hôpital Jean Verdier - APHP, Bondy, France
| | - Joël Schlatter
- Laboratoire de toxicologie de médecine légale, Hôpital Jean Verdier - APHP, Bondy, France
| |
Collapse
|
43
|
Chiadmi F, Schlatter J. Simultaneous determination of cotinine and trans-3-hydroxycotinine in urine by automated solid-phase extraction using gas chromatography-mass spectrometry. Biomed Chromatogr 2014; 28:453-8. [PMID: 24616054 PMCID: PMC4314699 DOI: 10.1002/bmc.3159] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 12/23/2013] [Accepted: 01/16/2014] [Indexed: 11/24/2022]
Abstract
A gas chromatography–mass spectrometry method was developed and validated for the simultaneous automated solid-phase extraction and quantification of cotinine and trans-3-hydroxycotinine in human urine. Good linearity was observed over the concentration ranges studied (R2 > 0.99). The limit of quantification was 10 ng/mL for both analytes. The limits of detection were 0.06 ng/mL for cotinine (COT) and 0.02 ng/mL for trans-3-hydroxycotinine (OH-COT). Accuracy for COT ranged from 0.98 to 5.28% and the precision ranged from 1.24 to 8.78%. Accuracy for OH-COT ranged from −2.66 to 3.72% and the precision ranged from 3.15 to 7.07%. Mean recoveries for cotinine and trans-3-hydroxycotinine ranged from 77.7 to 89.1%, and from 75.4 to 90.2%, respectively. This analytical method for the simultaneous measurement of cotinine and trans-3-hydroxycotinine in urine will be used to monitor tobacco smoking in pregnant women and will permit the usefulness of trans-3-hydroxycotinine as a specific biomarker of tobacco exposure to be determined. © 2014 The Authors. Biomedical Chromatography published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- Fouad Chiadmi
- Laboratoire de toxicologie de médecine légale, Hôpital Jean Verdier - APHP, Avenue du 14 juillet, 93140, Bondy, France
| | | |
Collapse
|
44
|
Auvity S, Chiadmi FM, Cisternino S, Fontan JE, Schlatter J. Stability of betaxolol suspensions in oral syringes and glass bottles. Ann Pharmacother 2013; 47:1237-8. [PMID: 24259746 DOI: 10.1177/1060028013503137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
|
46
|
Schlatter J. [Medication noncompliance: an act against its own existence]. Soins 2013:23-26. [PMID: 23785964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Stay safe, take no risk to his life, seems to be reasonable goal that everyone should continue. Some patients do not follow the recommendations of the caregivers, even when they are aware that the behavior of non-compliance is bad for them. The causes of this unreasonable conduct can be understood by the concept of weakness of will or akrasia, but also by addressing the beliefs, desires, and emotions of the patient with a chronic condition.
Collapse
Affiliation(s)
- Joël Schlatter
- laboratoire de toxicologie de médecine légale, hôpital Jean-Verdier, Hôpitaux universitaires Paris-Seine-Saint-Denis, Bondy, France.
| |
Collapse
|
47
|
Schlatter J, Chiadmi F, Gandon V, Chariot P. Simultaneous determination of methanol, acetaldehyde, acetone, and ethanol in human blood by gas chromatography with flame ionization detection. Hum Exp Toxicol 2013; 33:74-80. [PMID: 23584355 DOI: 10.1177/0960327113482845] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Methanol, acetaldehyde, acetone, and ethanol, which are commonly used as biomarkers of several diseases, in acute intoxications, and forensic settings, can be detected and quantified in biological fluids. Gas chromatography (GC)-mass spectrometry techniques are complex, require highly trained personnel and expensive materials. Gas chromatographic determinations of ethanol, methanol, and acetone have been reported in one study with suboptimal accuracy. Our objective was to improve the assessment of these compounds in human blood using GC with flame ionization detection. METHODS An amount of 50 µl of blood was diluted with 300 µl of sterile water, 40 µl of 10% sodium tungstate, and 20 µl of 1% sulphuric acid. After centrifugation, 1 µl of the supernatant was injected into the gas chromatograph. We used a dimethylpolysiloxane capillary column of 30 m × 0.25 mm × 0.25 µm. RESULTS We observed linear correlations from 7.5 to 240 mg/l for methanol, acetaldehyde, and acetone and from 75 to 2400 mg/l for ethanol. Precision at concentrations 15, 60, and 120 mg/l for methanol, acetaldehyde, and acetone and 150, 600, and 1200 mg/ml for ethanol were 0.8-6.9%. Ranges of accuracy were 94.7-98.9% for methanol, 91.2-97.4% for acetaldehyde, 96.1-98.7% for acetone, and 105.5-111.6% for ethanol. Limits of detection were 0.80 mg/l for methanol, 0.61 mg/l for acetaldehyde, 0.58 mg/l for acetone, and 0.53 mg/l for ethanol. CONCLUSION This method is suitable for routine clinical and forensic practices.
Collapse
Affiliation(s)
- J Schlatter
- 1Unit of Forensic Toxicology, Hôpital Jean-Verdier (AP-HP), Bondy, France
| | | | | | | |
Collapse
|
48
|
Auvity S, Chiadmi F, Cisternino S, Fontan JE, Schlatter J. A Rapid Stability-Indicating RP-HPLC Method for the Determination of Betaxolol Hydrochloride in Pharmaceutical Tablets. Anal Chem Insights 2013; 8:1-7. [PMID: 23531643 PMCID: PMC3603494 DOI: 10.4137/aci.s11256] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A stability-indicating reversed-phase high performance liquid chromatography (RP-HPLC) method was developed for the determination of betaxolol hydrochloride, a drug used in the treatment of hypertension and glaucoma. The desired chromatographic separation was achieved on a Nucleosil C18, 4 μm (150 × 4.6 mm) column, using isocratic elution at a 220 nm detector wavelength. The optimized mobile phase consisted of a 0.02 M potassium dihydrogen phosphate: methanol (40:60, v/v, pH 3.0 adjusted with o- phosphoric acid) as solvent. The flow rate was 1.6 mL/min and the retention time of betaxolol hydrochloride was 1.72 min. The linearity for betaxolol hydrochloride was in the range of 25 to 200 μg/mL. Recovery for betaxolol hydrochloride was calculated as 100.01%–101.35%. The stability-indicating capability was established by forced degradation experiments and the separation of unknown degradation products. The developed RP-HPLC method was validated according to the International Conference on Harmonization (ICH) guidelines. This validated method was applied for the estimation of betaxolol hydrochloride in commercially available tablets.
Collapse
Affiliation(s)
- Sylvain Auvity
- Unit of Pharmacy, Hôpital Jean Verdier (APHP), Bondy, France
| | | | | | | | | |
Collapse
|
49
|
|
50
|
Taleb C, Landre T, Bertrand E, Schlatter J, Ratiney R, des Guetz G. [Assessment of nursing needs and risk management in geriatric oncology]. Soins Gerontol 2013:35-39. [PMID: 23409678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
In France, the incidence and rate of mortality of cancer increase with age. For elderly patients suffering from cancer, the standard geriatric assessment, together with an oncological assessment aims to optimise the treatment. This geriatric oncology assessment enables the priorities to be identified and the cancer treatment to be adapted by anticipating the risks and organising the support care.
Collapse
Affiliation(s)
- Cherifa Taleb
- Service de SSR oncogériatrique, hôpital René-Muret (AP-HP), Sevran, France
| | | | | | | | | | | |
Collapse
|